Sydney-based Harrison.ai has announced the successful completion of its Series C funding round, securing $112 million (approximately AUD 179 million). This substantial investment underscores the company’s rapid growth and its pivotal role in transforming medical diagnostics through artificial intelligence (AI).

Founded in 2018 by brothers Dr. Aengus Tran and Dr. Dimitry Tran, Harrison.ai has swiftly emerged as a leader in the application of AI to medical imaging. The company’s mission is to leverage advanced AI technologies to enhance the accuracy and efficiency of medical diagnostics, thereby improving patient outcomes and addressing critical challenges in healthcare delivery.

The Series C funding round was led by existing investors, including prominent venture capital firms and strategic partners. This latest infusion of capital brings Harrison.ai’s total funding to date to over $200 million, following a $97 million Series B round in November 2021.

With the new funding, Harrison.ai aims to accelerate the development and deployment of its AI-powered diagnostic solutions across various medical specialties. The company plans to expand its international presence, particularly in markets such as the United States and Europe, where there is a growing demand for innovative healthcare technologies.

Read also: KODE Health Raises $27M to Transform Medical Coding and Data Management

Additionally, Harrison.ai intends to invest in research and development to enhance its existing AI models and explore new applications in areas like pathology and genomics. The company is also focused on strengthening partnerships with healthcare providers and institutions to facilitate the integration of its solutions into clinical workflows.

Harrison.ai’s AI-driven platforms have the potential to revolutionize medical diagnostics by providing clinicians with tools that offer rapid and accurate interpretations of medical images. This capability is particularly crucial in addressing the global shortage of radiologists and the increasing demand for diagnostic services.

By augmenting the diagnostic process, Harrison.ai aims to reduce the burden on healthcare professionals, minimize diagnostic errors, and ultimately improve patient care. The company’s solutions are designed to seamlessly integrate into existing healthcare systems, ensuring that they complement rather than disrupt clinical practices.

Read also: Neko Health Secures $260M to Transform Preventive Healthcare with AI-Driven Full-Body Scanning

The successful Series C funding round reflects the confidence of investors in Harrison.ai’s vision and the growing recognition of the importance of AI in healthcare. Industry experts note that the integration of AI into medical diagnostics represents a significant advancement in the pursuit of more efficient and effective healthcare delivery.

Harrison.ai’s approach to developing clinically validated AI solutions in collaboration with healthcare professionals has been highlighted as a key factor in its success. This collaborative model ensures that the technology is tailored to meet the practical needs of clinicians and patients alike.

As Harrison.ai continues to innovate and expand, the company is well-positioned to play a leading role in the transformation of healthcare through AI. The new funding will enable the company to scale its operations, enhance its product offerings, and reach more patients and healthcare providers globally.

With a strong foundation and a clear vision, Harrison.ai is poised to make significant contributions to the advancement of medical diagnostics and the improvement of patient outcomes worldwide.